HRPK20050421B3 - Agregat s povećanom deformabilnosti, koji sadrži barem tri amfipata, za poboljšani transport kroz polupropusne barijere i neinvazivnu primjenu lijekova in vivo, posebno kroz kožu - Google Patents

Agregat s povećanom deformabilnosti, koji sadrži barem tri amfipata, za poboljšani transport kroz polupropusne barijere i neinvazivnu primjenu lijekova in vivo, posebno kroz kožu

Info

Publication number
HRPK20050421B3
HRPK20050421B3 HR20050421A HRP20050421A HRPK20050421B3 HR PK20050421 B3 HRPK20050421 B3 HR PK20050421B3 HR 20050421 A HR20050421 A HR 20050421A HR P20050421 A HRP20050421 A HR P20050421A HR PK20050421 B3 HRPK20050421 B3 HR PK20050421B3
Authority
HR
Croatia
Prior art keywords
amphipathic
component
aggregate
skin
components
Prior art date
Application number
HR20050421A
Other languages
English (en)
Croatian (hr)
Inventor
Cevc Gregor
Vierl Ulrich
Original Assignee
Idea Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/357,617 external-priority patent/US7473432B2/en
Application filed by Idea Ag filed Critical Idea Ag
Publication of HRP20050421A2 publication Critical patent/HRP20050421A2/hr
Publication of HRPK20050421B3 publication Critical patent/HRPK20050421B3/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR20050421A 2002-10-11 2003-10-09 Agregat s povećanom deformabilnosti, koji sadrži barem tri amfipata, za poboljšani transport kroz polupropusne barijere i neinvazivnu primjenu lijekova in vivo, posebno kroz kožu HRPK20050421B3 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41784702P 2002-10-11 2002-10-11
US10/357,617 US7473432B2 (en) 2002-10-11 2003-02-04 NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US10/357,618 US20040105881A1 (en) 2002-10-11 2003-02-04 Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
PCT/EP2003/011202 WO2004032900A1 (en) 2002-10-11 2003-10-09 Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin

Publications (2)

Publication Number Publication Date
HRP20050421A2 HRP20050421A2 (en) 2005-12-31
HRPK20050421B3 true HRPK20050421B3 (hr) 2007-06-30

Family

ID=32995875

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050421A HRPK20050421B3 (hr) 2002-10-11 2003-10-09 Agregat s povećanom deformabilnosti, koji sadrži barem tri amfipata, za poboljšani transport kroz polupropusne barijere i neinvazivnu primjenu lijekova in vivo, posebno kroz kožu

Country Status (21)

Country Link
EP (5) EP1551370B1 (enExample)
JP (3) JP2006505619A (enExample)
KR (1) KR20050055723A (enExample)
CN (1) CN1703199B (enExample)
AT (1) ATE381316T1 (enExample)
AU (1) AU2003273977B2 (enExample)
BR (1) BR0315148A (enExample)
CA (1) CA2498938A1 (enExample)
DE (1) DE60318227T2 (enExample)
DK (1) DK1551370T3 (enExample)
EA (1) EA010407B1 (enExample)
ES (1) ES2298566T3 (enExample)
HR (1) HRPK20050421B3 (enExample)
IS (1) IS7776A (enExample)
MX (1) MXPA05003744A (enExample)
NO (1) NO20052281L (enExample)
NZ (1) NZ538571A (enExample)
PL (1) PL377202A1 (enExample)
PT (1) PT1551370E (enExample)
SI (1) SI1551370T1 (enExample)
WO (1) WO2004032900A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE216875T1 (de) 1999-01-27 2002-05-15 Idea Ag Nichtinvasive impfung durch die haut
PT1031347E (pt) 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
MXPA02000053A (es) 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US7473432B2 (en) 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
EP1811961A2 (en) * 2004-11-12 2007-08-01 Idea Ag Extended surface aggregates in the treatment of skin conditions
CN101842118B (zh) * 2007-09-13 2012-08-08 巴斯夫欧洲公司 疏水蛋白多肽作为渗透增强剂的用途
PL214538B1 (pl) * 2009-05-28 2013-08-30 P P F Hasco Lek Spolka Akcyjna Kompozycja liposomowa zawierajaca naproksen i sposób wytwarzania kompozycji liposomowej zawierajacej naproksen
WO2010140061A2 (en) * 2009-06-03 2010-12-09 John Charles Mayo Formulations for the treatment of deep tissue pain
DE112010003355T5 (de) * 2009-08-21 2012-07-12 Targeted Delivery Technologies Ltd. Veskuläre Formulierungen
US20140017301A1 (en) * 2011-03-21 2014-01-16 Gregor Cevc Drug-free compositions and methods for diminishing peripheral inflammation and pain
DE112012001386T5 (de) * 2011-03-21 2013-12-19 Gregor Cevc Optimierte Präparate von sehr anpassungsfähigen Aggregaten
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
CN104936682B (zh) * 2012-10-26 2017-12-15 牛津纳米孔技术公司 微滴界面
RU2524649C1 (ru) * 2013-07-24 2014-07-27 Станислав Анатольевич Кедик Способ получения микросфер для приготовления инъецируемой лекарственной формы диклофенака, композиция и лекарственная форма
CN105473162A (zh) * 2013-07-31 2016-04-06 斯昆申技术控股有限责任公司 囊泡
CN105764917B (zh) * 2013-09-26 2021-10-08 新加坡国立大学 利用溶血磷脂酰胆碱支架的组合物和方法
WO2015060446A1 (ja) * 2013-10-25 2015-04-30 凸版印刷株式会社 膜小胞回収デバイス、膜小胞回収方法、及び膜小胞分析方法
LT3316857T (lt) 2015-06-30 2021-11-25 Sequessome Technology Holdings Limited Daugiafazės kompozicijos
WO2017087685A1 (en) 2015-11-20 2017-05-26 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
US12514929B2 (en) 2017-04-03 2026-01-06 The Regents Of The University Of California Deformable nano-scale vehicles (DNVS) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
KR102149190B1 (ko) 2018-04-09 2020-08-28 경상대학교산학협력단 액중 방전 마이크로젯 약물 전달장치
EP3955918A1 (en) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
CN115667217A (zh) 2020-05-19 2023-01-31 赛本爱尔兰有限公司 氘化的色胺衍生物和使用方法
KR102209397B1 (ko) 2020-07-21 2021-01-29 경상대학교산학협력단 액중 방전 마이크로젯 약물 전달장치

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4107153A1 (de) * 1991-03-06 1992-09-10 Gregor Cevc Praeparat zur wirkstoffapplikation in kleinsttroepfchenform
CA2067754C (en) * 1990-08-24 2002-06-04 Gregor Cevc Preparation for the application of agents in mini-droplets
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
DE4447287C1 (de) * 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
ES2226203T3 (es) * 1998-12-23 2005-03-16 Idea Ag Formulacion mejorada para aplicacion topica no invasiva.
PT1031347E (pt) * 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis

Also Published As

Publication number Publication date
KR20050055723A (ko) 2005-06-13
NZ538571A (en) 2007-05-31
HK1079113A1 (en) 2006-03-31
WO2004032900A1 (en) 2004-04-22
EP1829527A2 (en) 2007-09-05
EP1815846A2 (en) 2007-08-08
WO2004032900A8 (en) 2005-03-31
PL377202A1 (pl) 2006-01-23
EA010407B1 (ru) 2008-08-29
EP1815846A3 (en) 2008-10-22
JP4555111B2 (ja) 2010-09-29
PT1551370E (pt) 2008-02-07
BR0315148A (pt) 2005-08-16
CA2498938A1 (en) 2004-04-22
ES2298566T3 (es) 2008-05-16
NO20052281L (no) 2005-07-07
AU2003273977A1 (en) 2004-05-04
DE60318227D1 (de) 2008-01-31
EP1551370B1 (en) 2007-12-19
SI1551370T1 (sl) 2008-06-30
JP2006505619A (ja) 2006-02-16
EP1829528A3 (en) 2008-11-05
EP1815847A2 (en) 2007-08-08
NO20052281D0 (no) 2005-05-10
ATE381316T1 (de) 2008-01-15
DE60318227T2 (de) 2008-12-04
CN1703199B (zh) 2010-04-28
DK1551370T3 (da) 2008-03-03
EP1829528A2 (en) 2007-09-05
JP2005213261A (ja) 2005-08-11
CN1703199A (zh) 2005-11-30
MXPA05003744A (es) 2005-09-20
EA200500632A1 (ru) 2005-12-29
HRP20050421A2 (en) 2005-12-31
EP1829527A3 (en) 2008-11-05
JP2009108070A (ja) 2009-05-21
EP1551370A1 (en) 2005-07-13
IS7776A (is) 2005-03-30
EP1815847A3 (en) 2008-11-05
AU2003273977B2 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
HRPK20050421B3 (hr) Agregat s povećanom deformabilnosti, koji sadrži barem tri amfipata, za poboljšani transport kroz polupropusne barijere i neinvazivnu primjenu lijekova in vivo, posebno kroz kožu
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
WO2002080941A1 (en) Compositions for preparing external carbon dioxide agents
EA200901112A1 (ru) Жидкие композиции, образующие дермальные пленки, для введения лекарственных препаратов в кожу
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
MX272772B (es) Composiciones formadoras de pelicula para proteger la piel de fluidos corporales y articulos elaborados a partir de las mismas.
BRPI0714417B8 (pt) método para fabricar uma composição de cuidado oral, de cuidado pessoal, limpadora e/ou de cuidado doméstico
AR028512A1 (es) Composiciones antimicrobianas acidas para el tratamiento de alimentos y superficies que contactan alimentos y metodos para la utilizacion de estas
EP1163902A3 (en) Transdermal preparation containing hydrophilic or salt-form drug
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
ES2178048T3 (es) Uso de rifaximina como medicamento para el tratamiento de diarrea por criptosporidiosis.
MXPA04001328A (es) Productos en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otros ingredientes activos, y su uso.
TW200633978A (en) 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
HRP20150120T1 (hr) Materijal i metode za lijeäśenje poremeä†aja u razvoju ukljuäśujuä†i komorbidni i idiopatski autizam
AR036357A1 (es) Composicion de gel endoparasiticida, un metodo para su preparacion y el uso de dicha composición para la manufactura de un medicamento.
EP2206490A3 (en) Adherent and erodible film to treat a moist surface of a body tissue
CL2004001012A1 (es) Compuestos derivados de macrolidos de 14 o 15 miembros, sustituidos en posicion 4"; procedimiento para su preparacion; composicion farmaceutica que lo comprende; y su uso para el tratamiento o profilaxis de infecciones microbianas sistemicas o topica
BR0311965A (pt) Formulações estabilizadas de antagonistas de receptores alfa adrenérgicos e os seus usos
KR20190079909A (ko) 발포 입욕제 조성물
ATE468130T1 (de) Inhibitoren der kostimulation via ox40 und deren verwendung gegen eine von virusen induzierten immunpathologie
CL2004001007A1 (es) Compuestos derivados de macrolitos de 14 o 15 miembros, sustituidos en posicion 4"; procedimiento para su preparacion; composicion farmaceutica que lo comprende; y su uso para el tratamiento o profilaxis de infecciones microbianas sistemicas o topica
TW200635925A (en) Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
AR029557A1 (es) Composicion para el uso en el tratamiento o la prevencion de la mastitis, y uso de oxazolidinona para la fabricacion de un medicamento para el tratamiento o la prevencion de la mastitis
CL2004001009A1 (es) Compuestos derivados de macrolidos de 14 o 15 miembros, sustituidos en posicion 4"; procedimiento para su preparacion; composicion farmaceutica que lo comprende; y su uso para el tratamiento o profilaxis de infecciones microbianas sistemicas o topica

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AKOB Publication of a request for the grant of a patent not including a substantive examination of a patent application (a consensual patent)
PKB1 Consensual patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20110722

Year of fee payment: 9

PBKO Lapse due to non-payment of renewal fee for consensual patent

Effective date: 20121010